Neurocrine Biosciences to Present at the Nomura Biotechnology ConferenceLive Audio Webcast will be on November 6 2014
SAN DIEGO Nov. 3 2014
SAN DIEGO Nov. 3 2014 /PRNewswire/ — Neurocrine Biosciences Inc. (Nasdaq: NBIX) announced today that Kevin Gorman President and Chief Executive Officer of Neurocrine Biosciences will be presenting at the Nomura Biotechnology Conference in Boston.
The live presentation takes place on Thursday November 6 at 11:30am ET (8:30am PT).The presentation will be webcast and may be accessed on the Company’s website at http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences Inc. discovers and develops innovative and life-changing pharmaceuticals in diseases with high unmet medical needs through its novel R&D platform focused on neurological and endocrine based diseases and disorders.The Company’s two lead late-stage clinical programs are elagolix a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc. and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.Neurocrine Biosciences Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.
SOURCENeurocrine Biosciences Inc.